Propanc Biopharma, Inc. (PPCB) - Dilution Analysis

8-K filing: Propanc Biopharma, Inc. closed a private placement transaction with Hexstone Capital LLC, issuing 100 shares of Series C Preferred Stock and a warrant to purchase up to 9,900 additional shares of Series C Preferred Stock for $1,000,099. ($2.0M proceeds)

8-K filing: Propanc Biopharma., Inc. entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock, convertible into common stock, with the Company issuing 100 shares of Series C Preferred Stock and a warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock upon closing.

8-K filing: Propanc Biopharma., Inc. completed a public offering of 1,000,000 shares of common stock at $4.00 per share, with D. Boral Capital, LLC as the underwriter, and issued warrants to the representative to purchase 30,000 shares at $4.00 per share. ($4.0M proceeds)

S-1/A filing: Propanc Biopharma, Inc. is offering 1,000,000 shares of common stock at an assumed public offering price of $5.00 per share.

8-K filing: Propanc Biopharma, Inc. issued a Promissory Note to an accredited investor for a purchase price of $75,000, with the intention to use the net proceeds for general working capital purposes. ($0.08M proceeds)

S-1/A filing: Propanc Biopharma, Inc. is offering 1,000,000 shares of common stock at an assumed public offering price of $5.00 per share.

10-Q filing | 11.6M shares outstanding

S-1/A filing: Propanc Biopharma, Inc. is offering 1,000,000 shares of common stock at an estimated public offering price of $4.00-6.00 per share.

S-1/A filing: Propanc Biopharma, Inc. is offering 1,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of Common Stock at an estimated public offering price at $4.00-6.00 per Unit.

S-1/A filing: Propanc Biopharma, Inc. is offering 1,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at an estimated public offering price of $4.00-6.00 per Unit.

S-1/A filing: Propanc Biopharma, Inc. is offering 1,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.

10-Q filing | 0.0M shares outstanding

10-Q filing | 789.9M shares outstanding

S-1 filing: Propanc Biopharma, Inc. is offering 1,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.

10-K filing | 688.0M shares outstanding

10-Q filing | 168.0M shares outstanding

10-Q filing | 52.1M shares outstanding

10-Q filing | 22.3M shares outstanding

S-1/A filing: This S-1/A filing relates to the offer and resale of up to 26,250,000 shares of common stock by a selling stockholder, with the company potentially receiving up to $5 million in gross proceeds for product development, working capital, and general corporate purposes.

S-1/A filing: This S-1/A filing relates to the offer and resale of up to 26,250,000 shares of common stock by Dutchess Capital Growth Fund L.P. pursuant to a common stock purchase agreement, with the company potentially receiving up to $5 million in gross proceeds.

10-K filing | 14.8M shares outstanding

S-1 filing: This S-1 filing relates to the offer and resale of up to 26,250,000 shares of common stock by Dutchess Capital Growth Fund L.P. pursuant to a common stock purchase agreement. The company may receive up to $5 million in aggregate gross proceeds.

8-K filing: Propanc Biopharma, Inc. entered into a securities purchase agreement with an investor for a $65,000 convertible promissory note and a loan agreement with an institutional investor for AU$230,000, issuing a warrant exercisable for 15,000,000 common shares at $0.01 per share.

8-K filing: Propanc Biopharma, Inc. entered into a stock purchase agreement with an institutional investor for up to $5,000,000 of common stock, issued a 10% unsecured convertible promissory note with an aggregate face value of $125,000, and issued an aggregate of 75,000,000 shares of common stock to the investor. ($0.15M proceeds)

10-Q filing | 3288.4M shares outstanding

8-K filing: Stock split 1-for-1000 | Outstanding: 1,763,908,545 → 1,763,908

POS AM filing: The Selling Stockholder may offer Common Stock from time to time at prevailing market prices, fixed prices, negotiated prices, or varying prices.

10-Q filing | 1763.9M shares outstanding

10-Q filing | 889.7M shares outstanding

10-K filing | 677.2M shares outstanding

10-Q filing | 122.2M shares outstanding

10-Q filing | 61.4M shares outstanding

S-1 filing: This S-1 filing outlines a proposed equity line offering with Dutchess Capital Growth Fund LP, potentially offering up to $5,000,000 worth of common stock over a 36-month period, but the amount registered in this statement is for an offering of approximately $728,640 based on the lowest market price of the common stock.

10-Q filing | 49.9M shares outstanding

10-K filing | 41.1M shares outstanding

8-K filing: Propanc Biopharma issued 5,928,000 shares of common stock to James Nathanielsz and 3,420,000 shares of common stock to Dr. Julian Kenyon in exchange for cancellation of debt and accrued salary. ($0.28M proceeds)

10-Q filing | 6.0M shares outstanding

10-Q filing | 3.6M shares outstanding

8-K filing: Stock split 1-for-1,000 | Outstanding: 691,170,618 → 688,671

10-Q filing | 691.2M shares outstanding

S-1/A filing: The Selling Stockholder may offer common stock at a fixed price of $0.00181 until the shares are quoted on the OTCQB or OTCQX marketplaces, or listed on a national securities exchange.

10-K filing | 688.7M shares outstanding

S-1/A filing: This prospectus relates to the offering and resale by the Selling Stockholder identified herein of up to 150,000,000 shares of Common Stock of Propanc Biopharma, Inc.

S-1/A filing: This prospectus relates to the offering and resale by the Selling Stockholder identified herein of up to 150,000,000 shares of Common Stock of Propanc Biopharma, Inc.

S-1/A filing: This prospectus relates to the offering and resale by the Selling Stockholder of up to 150,000,000 shares of Common Stock of Propanc Biopharma, Inc., including shares underlying units and warrants.

10-Q filing | 47.1M shares outstanding

S-1 filing: This prospectus relates to the offering and resale by the Selling Stockholder identified herein of up to 150,000,000 shares of Common Stock of Propanc Biopharma, Inc.

8-K filing: Propanc Biopharma, Inc. sold 7,500,000 units to an investor for $450,000, each unit consisting of 1.5 shares of common stock (or pre-funded warrants) and 1.5 warrants, and also issued 63,750,000 Series B warrants and 63,750,000 Series C warrants. ($0.45M proceeds)

10-Q filing | 5.2M shares outstanding

S-1/A filing: The filing is an S-1/A form for a common stock offering, with a proposed offering price of $0.18 per share, estimated for registration fee purposes based on the OTCQB closing bid price on December 3, 2019. The Selling Security Holder may sell shares at the current market price.